Keloid Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Veröffentlicht von: precision business insights
Veröffentlicht am: 20.02.2018 10:58
Rubrik: Gesundheit & Medizin

(Presseportal openBroadcast) - Keloid Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023


Keloid Treatment Market:
By Type (Compression Therapy, Intralesional Corticosteroid Injections, Occlusive Dressing, Excision, Cryosurgery, Laser Therapy, Radiation Therapy, Interferon Therapy) By End User (Hospitals, Beauty Centres, Dermatology Clinics, Others) and Geography (Latin America, North America, Asia- Pacific, The Middle East & Africa and Europe) – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023

Market Outline: Keloid Treatment Market

An abnormal proliferation of a scar tissue which farms at site of cutaneous injury is called as keloid. Keloid scar doesn’t regress and progress beyond the scar’s original margin and it can reduce over a period of time. Keloids are the benign fibroproliferative dermal tumours.

A sample of this report is available upon request @

Market Dynamics: Keloid Treatment Market

Adoption of technological advancements in derma care, increase in awareness among the people regarding treatment for the keloids expected to fuel the keloid treatment market. Furthermore, lifestyle changes, growing beauty consciousness, rise in personal care expenditure, growing acceptance of the patients to various treatment approaches are the factors which are expected to boost the growth of the market. However, lack of awareness, adverse effects regarding the treatment, high cost of treatment are major restraints of the market.

Market Scope: Keloid Treatment Market

Keloid Treatment Market is segmented based on type, end user and geography

Based on type, it is segmented into

• Compression Therapy
• Intralesional Corticosteroid Injections
• Occlusive Dressing
• Excision
• Cryosurgery
• Laser Therapy
• Radiation Therapy
• Interferon Therapy

Based on end user, it is segmented into

• Hospitals
• Beauty Centres
• Dermatology Clinics
• Others
To view TOC of this report is available upon request @

Market overview: Keloid Treatment Market

As per National Institute of Health, Keloid scars are most common in people with age group of 10-30 years. Keloid scars are commonly seen in African Americans, Asians, or Hispanic descents. Growing consciousness regarding appearance and looks among people is the major driving factor for keloid treatment market. New product launches and innovations, mergers and acquisitions, partnerships and collaborations are few strategies adopted by companies in order to strengthen position in global keloid treatment market. For example, in 2015, An Israel aesthetic company Pollogen Ltd, was acquired by Lumenis in order to enhance its product portfolio.

Region Overview: Keloid Treatment Market

Geographically Keloid Treatment Market is divided into Latin America, North America, Asia Pacific, The Middle East and Africa and Europe. North America is expected to dominate the keloid treatment market due to high disposable income, high expenditure on the personal care and appearance. As per statistics of American Society of Plastic Surgeons, in 2014, about 10 Mn surgical and non-surgical aesthetic surgeries were performed in U.S. Europe is driven by high adoption of technological advancements, high awareness regarding scar treatments. Asia-Pacific keloid treatment market is expanding at a rapid growth owing to growing awareness about the appearance and looks, health concerns, rise in per capita income.

Need more information about this report @

Competition Assessment: Keloid Treatment Market

Key player’s profiles in Keloid Treatment Market include

• GlaxoSmithKline Plc. (UK)
• Avita Medical.(UK)
• Pacific World Corporation (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Renovo Group plc. (UK)
• Novartis AG (Switzerland)
• Valeant Pharmaceuticals International Inc., (Canada)
• RXi Pharmaceuticals, Inc. (U.S.)
• Galena Biopharma, Inc., (U.S.)

Get access to full summary @

Bitte beachten Sie, dass für den Inhalt der hier veröffentlichten Meldung nicht openBroadcast verantwortlich ist, sondern der Verfasser der jeweiligen Meldung selbst. AGB | Haftungsausschluss.